All In Biotech

Drug Trial Radar · NCT07567872

A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Jul 9, 2026

Primary completion

Sep 2026

Study completion Sep 2026

Sponsor

Sponsor type
Industry
First posted
May 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation administered in a single dose in healthy individuals and multiple doses in patients with COPD。

Conditions

  • COPD

Interventions

  • HRS-9821 Powder for InhalationDrug

    HRS-9821 Powder for Inhalation

  • PlaceboDrug

    placebo for HRS-9821 Powder Inhalation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the rate of adverse eventsTime frame: The screening period lasted until 26days after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.